source
- Ascletis pursues oral IL-17A inhibitor for psoriasis as Invivyd readies COVID-19 filingAscletis, a biotech listed in Hong Kong, is developing a small‑molecule IL-17A inhibitor in pill form to treat psoriasis. The company aims to challenge the current injectable therapies that target…
- UniQure shares tumble as Huntington's gene therapy shows reduced benefit over timeUniQure announced new follow-up data from its experimental gene therapy for Huntington's disease, indicating the treatment's effect may diminish with longer observation. The additional year of dat…